

Astellas Announces Changes in Management Structure and Global Function

Tokyo, February 8, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the changes in its top management structure and global function effective April 1, 2017 as below.

1. Top Management Structure

Top Management	Divisional/Functional Responsibilities
Yoshihiko Hatanaka CEO	Internal Auditing, External Relations, Drug Discovery Research, Pharmaceutical Technology, Legal, Intellectual Property, AIRM
Kenji Yasukawa CSTO & CCO	Corporate Planning, Product & Portfolio Strategy, Business Development, Japan Sales & Marketing, Asia & Oceania Business, EMEA Operations, Americas Operations, MS
Sef Kurstjens CMO	Dev, PV, MA, RA, CRQA, QA
Chikashi Takeda CFO	Corporate Finance & Control, Accounting & Tax, Corporate Communications, Procurement, Information Systems, RWI
Fumiaki Sakurai CAO & CEEO	Healthcare Policy & CSR, General Affairs, Human Resources, Ethics & Compliance, Executive Office

CEO: Chief Executive Officer

CSTO: Chief Strategy Officer

CCO: Chief Commercial Officer

CMO: Chief Medical Officer

CFO: Chief Financial Officer

CAO: Chief Administrative Officer

CEEO: Chief Ethics & Compliance Officer

AIRM: Astellas Institute for Regenerative Medicine

EMEA: Europe, Middle East and Africa

MS: Marketing Strategy

Dev: Development

PV: Pharmacovigilance

MA: Medical Affairs

RA: Regulatory Affairs
CRQA: Clinical and Research Quality Assurance
QA: Quality Assurance
RWI: Real World Informatics and Analytics

2. Global Function

Enhancement of Legal

To better address the global business environment and assure high-quality legal function across organization, a new global function, “Legal” that will manage the regional legal functions will be established. The General Counsel will report directly to CEO and also serve as a standing member of the Executive Committee.

Enhancement of Intellectual Property

In order to protect our intellectual property and strengthen functional support to internal stakeholders, a new global function, “Intellectual Property” that will manage the regional intellectual property functions will be established. The Head of Intellectual Property will report directly to CEO.

Restructuring of Technology

In order to strengthen its global operations and contract manufacturing organization management, and to enhance administrative structure, Technology will be restructured into new function structure and will be named as “Pharmaceutical Technology” to accurately emphasize its function in the manufacture of pharmaceutical products.

###

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473